Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant

Stephen Michael Clark, Amber B. Clemmons, Lindsay Schaack, Jeonifer Garren, David L. Deremer, Vamsi Kota

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Methods In a single-center cohort study patients receiving melphalan containing hematopoietic stem cell transplantation regimens who received a one-time dose of 150 mg IV fosaprepitant (n = 56) were compared to a historical control (n = 70). Results The primary endpoint of no emesis from melphalan administration through five days afterward was 80% for the fosaprepitant group versus 66% in the control group (p = 0.068). Addition of fosaprepitant demonstrated significant improvement in emetic episodes per patient during the entire assessment period (p = 0.011) and days 1-5 after melphalan (p = 0.045). Fosaprepitant resulted in no substantial nausea during the entire assessment period in 37% of high-dose melphalan patients and 57% of BEAM patients. Conclusions Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting.

Original languageEnglish (US)
Pages (from-to)416-422
Number of pages7
JournalJournal of Oncology Pharmacy Practice
Volume22
Issue number3
DOIs
StatePublished - Jan 1 2016

Fingerprint

fosaprepitant
Melphalan
Hematopoietic Stem Cells
Nausea
Vomiting
Transplants
Hematopoietic Stem Cell Transplantation
Emetics
Cohort Studies

Keywords

  • fosaprepitant
  • hematopoietic stem cell transplant
  • nausea
  • vomiting

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. / Clark, Stephen Michael; Clemmons, Amber B.; Schaack, Lindsay; Garren, Jeonifer; Deremer, David L.; Kota, Vamsi.

In: Journal of Oncology Pharmacy Practice, Vol. 22, No. 3, 01.01.2016, p. 416-422.

Research output: Contribution to journalArticle

Clark, Stephen Michael ; Clemmons, Amber B. ; Schaack, Lindsay ; Garren, Jeonifer ; Deremer, David L. ; Kota, Vamsi. / Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. In: Journal of Oncology Pharmacy Practice. 2016 ; Vol. 22, No. 3. pp. 416-422.
@article{3dcc1bd4eff64bec998806a3335b241c,
title = "Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant",
abstract = "Purpose To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Methods In a single-center cohort study patients receiving melphalan containing hematopoietic stem cell transplantation regimens who received a one-time dose of 150 mg IV fosaprepitant (n = 56) were compared to a historical control (n = 70). Results The primary endpoint of no emesis from melphalan administration through five days afterward was 80{\%} for the fosaprepitant group versus 66{\%} in the control group (p = 0.068). Addition of fosaprepitant demonstrated significant improvement in emetic episodes per patient during the entire assessment period (p = 0.011) and days 1-5 after melphalan (p = 0.045). Fosaprepitant resulted in no substantial nausea during the entire assessment period in 37{\%} of high-dose melphalan patients and 57{\%} of BEAM patients. Conclusions Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting.",
keywords = "fosaprepitant, hematopoietic stem cell transplant, nausea, vomiting",
author = "Clark, {Stephen Michael} and Clemmons, {Amber B.} and Lindsay Schaack and Jeonifer Garren and Deremer, {David L.} and Vamsi Kota",
year = "2016",
month = "1",
day = "1",
doi = "10.1177/1078155215585190",
language = "English (US)",
volume = "22",
pages = "416--422",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant

AU - Clark, Stephen Michael

AU - Clemmons, Amber B.

AU - Schaack, Lindsay

AU - Garren, Jeonifer

AU - Deremer, David L.

AU - Kota, Vamsi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Methods In a single-center cohort study patients receiving melphalan containing hematopoietic stem cell transplantation regimens who received a one-time dose of 150 mg IV fosaprepitant (n = 56) were compared to a historical control (n = 70). Results The primary endpoint of no emesis from melphalan administration through five days afterward was 80% for the fosaprepitant group versus 66% in the control group (p = 0.068). Addition of fosaprepitant demonstrated significant improvement in emetic episodes per patient during the entire assessment period (p = 0.011) and days 1-5 after melphalan (p = 0.045). Fosaprepitant resulted in no substantial nausea during the entire assessment period in 37% of high-dose melphalan patients and 57% of BEAM patients. Conclusions Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting.

AB - Purpose To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Methods In a single-center cohort study patients receiving melphalan containing hematopoietic stem cell transplantation regimens who received a one-time dose of 150 mg IV fosaprepitant (n = 56) were compared to a historical control (n = 70). Results The primary endpoint of no emesis from melphalan administration through five days afterward was 80% for the fosaprepitant group versus 66% in the control group (p = 0.068). Addition of fosaprepitant demonstrated significant improvement in emetic episodes per patient during the entire assessment period (p = 0.011) and days 1-5 after melphalan (p = 0.045). Fosaprepitant resulted in no substantial nausea during the entire assessment period in 37% of high-dose melphalan patients and 57% of BEAM patients. Conclusions Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting.

KW - fosaprepitant

KW - hematopoietic stem cell transplant

KW - nausea

KW - vomiting

UR - http://www.scopus.com/inward/record.url?scp=84964296239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964296239&partnerID=8YFLogxK

U2 - 10.1177/1078155215585190

DO - 10.1177/1078155215585190

M3 - Article

VL - 22

SP - 416

EP - 422

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 3

ER -